Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate

British Journal of Clinical Pharmacology

Volumn 73, Issue 2, 2012, Pages 240-247

  Joerger, Markus ^a   Ferreri, Andrés J M ^b   Krähenbühl, Stephan ^c   Schellens, Jan H M ^d,e   Cerny, Thomas ^a   Zucca, Emanuele ^f   Huitema, Alwin D R ^d  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Bayesian estimate; CNS lymphoma; High dose chemotherapy; Methotrexate; Therapeutic drug monitoring

Indexed keywords

CYTARABINE; FOLINIC ACID; METHOTREXATE;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SIMULATION;

ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BAYES THEOREM; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; TREATMENT OUTCOME;

EID: 84855513195     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04084.x     Document Type: Article

References (35)

1. Herrlinger U, Kuker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, Bamberg M, Weller M. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005; 57: 843-7.
2. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10: 5643-6.
3. Calderoni A, Aebi S. Combination chemotherapy with high-dose methotrexate and cytarabine with or without brain irradiation for primary central nervous system lymphomas. J Neurooncol 2002; 59: 227-30.
4. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20: 4643-8.
5. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, Aondio GM, Ferrarese F, Gomez H, Ponzoni M, Borisch B, Berger F, Chassagne C, Iuzzolino P, Carbone A, Weis J, Pedrinis E, Motta T, Jouvet A, Barbui T, Cavalli F, Blay JY. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58: 1513-20.
6. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kuker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benohr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M, Weller M, German Cancer Society Neuro-Oncology Working Group. NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002; 51: 247-52.
7. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21: 1044-9.
8. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, Taphoorn M, Thomas J, Van den Bent M, Fickers M, Van Imhoff G, Rozewicz C, Teodorovic I, van Glabbeke M. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21: 4483-8.
9. Abrey LE. Hematology. Individualized methotrexate dosing in primary CNS lymphoma. Nat Rev Clin Oncol 2010; 7: 306-7.
10. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-50.
11. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009; 8: 581-92.
12. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002; 50: 373-82.
13. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094-104.
14. Isacoff WH, Morrison PF, Aroesty J, Willis KL, Block JB, Lincoln TL. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 1977; 61: 1665-74.
15. Schornagel JH, McVie JG. The clinical pharmacology of methotrexate. Cancer Treat Rev 1983; 10: 53-75.
16. Stewart AL, Margison JM, Wilkinson PM, Lucas SB. The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy. Cancer Chemother Pharmacol 1985; 14: 165-7.
17. Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006; 62: 71-80.
18. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766-75.
19. Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes A, Ferrarese F, Rognone A, Govi S, Dell'Oro S, Locatelli M, Villa E, Reni M. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004; 90: 353-8.
20. Joerger M, Huitema AD, Krahenbuhl S, Schellens JH, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri AJ. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102: 673-7.
21. Blasco H, Senecal D, Le Gouge A, Pinard E, Benz-de Bretagne I, Colombat P, Hulot JS, Chatelut E, Le Guellec C. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. Br J Clin Pharmacol 2010; 70: 367-75.
22. Bustad A, Terziivanov D, Leary R, Port R, Schumitzky A, Jelliffe R. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45: 365-83.
23. Jelliffe R, Schumitzky A, Van Guilder M. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. Ther Drug Monit 2000; 22: 354-65.
24. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986; 73: 645-56.
25. Bourguignon L, Goutelle S, De Saint-Martin JB, Maire P, Ducher M. Evaluation of various gentamicin dosage regimens in geriatric patients: a simulation study. Fundam Clin Pharmacol 2010; 24: 109-13.
26. Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, Schellens JH, Beijnen JH, Vermorken JB. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 2007; 64: 622-33.
27. Beal SS, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User's Guides 1989-2009. Ellicott City, MD: Icon Development Solutions, 2009.
28. Levitt M, Mosher MB, DeConti RC, Farber LR, Skeel RT, Marsh JC, Mitchell MS, Papac RJ, Thomas ED, Bertino JR. Improved therapeutic index of methotrexate with 'leucovorin rescue'. Cancer Res 1973; 33: 1729-34.
29. Goorin A, Strother D, Poplack D, Letvak LA, George M, Link M. Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma. Med Pediatr Oncol 1995; 24: 362-7.
30. Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ, O'Brien M, Adamson PC. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997; 15: 2125-34.
31. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-20.
32. Hiraga S, Arita N, Ohnishi T, Kohmura E, Yamamoto K, Oku Y, Taki T, Sato M, Aozasa K, Yoshimine T. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999; 91: 221-30.
33. Marcus RH, Hodson D, Coupland S, Bessell E, Mead B, Pettitt AR. Guidelines on the diagnosis and management of adult patients with primary CNS lymphoma (CNSL) and primary intra-ocular lymphoma (PIOL). 2009.
34. Iliadis A, Bachir-Raho M, Bruno R, Favre R. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. J Pharmacokinet Biopharm 1985; 13: 101-15.
35. Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit 2011; 33: 99-107.